Eisai, Merck in global oncology deal

By Sandi Wong | Mar 8, 2018 | 12:53 AM GMT

Eisai Co. Ltd. (Tokyo:4523) and Merck & Co. Inc. (NYSE:MRK) partnered worldwide to jointly develop and commercialize Eisai's cancer drug Lenvima lenvatinib